Introduction: Dispatches from the GUILD Conference 2022

Introduction: Dispatches from the GUILD Conference 2022

Read Article

Welcome to the Sixth annual Dispatches from GUILD series. The Gastrointestinal Updates-Inflammatory Bowel Disease Liver Disease (GUILD) Conference is an annual CME conference held in Maui, Hawaii every February (GUILD 2022: February 20-23). We were delighted to offer a hybrid meeting with over 200 health care providers attending live. GUILD again provided cutting edge updates in gastroenterology by world class speakers. Our topics this year included 2 days of IBD updates, a day of hepatology and a day devoted to common outpatient disorders. We understand that trainees are our future. Ten Gastroenterology fellows were selected to attend the meeting and receive daily mentoring and networking from our star faculty. GUILD also recognizes the role played by nurse practitioners and physician assistants in the care of IBD and Liver patients and introduced a boot camp in 2019, awarding 10 scholarships to APPs to attend the meeting.

To share our learning with the gastroenterology community at large, we are happy to continue our series beginning with the following article, “Managing Perianal Fistula”.

We look forward to providing informative and educational articles covering IBD, Hepatology and special topics in GI in Practical Gastroenterology over the following months. We look forward to seeing you all in person for GUILD 2023 in Maui February 18-22.

Download Tables, Images & References

BOOK REVIEWS

Got Guts? A Guide to Prevent and Beat Colon Cancer

Read Article

Title: Got Guts? A Guide to Prevent and Beat Colon Cancer
Authors: Joseph Weiss, MD, Nancy Cetel, MD,
Danielle Weiss, MD
Publisher: Smartask Books
Date: October 12, 2020
ISBN: 978-1-943760-97-8
Price: $14.95

Got Guts? A Guide to Prevent and Beat Colon Cancer by Jospeh Weiss, MD, Nancy Cetel, MD, and Danielle Weiss, MD, attempts to tackle the difficult topic of colon cancer screening. This has always been a topic of debate with many viewpoints, changing information, and more recently, newer methods of screening to be considered. The authors challenge the notion of colonoscopy superiority in screening and encourage other less invasive and less costly modalities to encourage more compliance with screening. The authors clearly understand the difference between population and individual risks, and outcomes. They truly favor the individual to just get screened, to not be embarrassed, to start screening early and to repeat often, much earlier in fact than even the most recent guidelines’ recommendations. The biggest challenge to colon cancer screening is education and outreach to the general population. More than one-third of Americans who should be screened for colon cancer do not participate or receive any method of screening. Unfortunately, a large number of those individuals also don’t routinely see a doctor for any reason making this issue all the more difficult to correct. Therefore, the authors have attempted to target the book to the general population and to encourage readers to discuss these topics with their friends and family who might not read the book or be aware of the need to screen for colon cancer. The book repeats information throughout the 136 pages to drive home points which hopefully make the recommendations more understandable to non-healthcare readers.

However, given the recitation of statistics and the thorough and comprehensive review of testing and screening options, it may still be difficult for the average patient to understand this book, and any decisions they make should always be in conjunction with a medical provider. Some recommendations, such as routine screening with saliva genetic testing before age 20 years, are not a part of any current medical guideline and therefore would be very difficult to get covered by insurance, leaving the ability to get the test to those who are willing to pay for it themselves. In healthcare, it is important for people to be aware of their options and to decide if it is worth it to them to pay for testing themselves. It is this kind of forward thinking that is what drives debate and is worthy of additional study so that practice guidelines can be further refined. Perhaps an added target audience would be primary care providers, who can then recommend the book to select patients who want more background to be able to participate knowledgeably in the shared decision making discussions about their own or their family’s healthcare.

Daniel Schlosser, MD

Dignity Health Medical Group,

Transitional Care

Phoenix, Arizona

Download Tables, Images & References

FROM THE LITERATURE

Role of EUS in Patients with Asymptomatic Vitamin D Intake and Risk of Colorectal Cancer

Read Article

While vitamin D has been implicated in colorectal cancer (CRC) pathogenesis, to determine the association between vitamin D intake and risks of early-onset CRC and precursors among women enrolled in Nurses’ Health Study II, the association was examined.

Multivariable-adjusted hazard ratios (HRs) for early-onset CRC were estimated with Cox proportional hazards model.  Multivariableadjusted odds ratios (ORs) for early-onset conventional adenomas and serrated polyps were estimated with logistic region model.

A total of 111 incident cases of early-onset CRC were documented during 1,250,560 person-years of followup (1991 to 2015). Higher total vitamin D intake was significantly associated with a reduced risk of early-onset

CRC (HR >450 IU/day vs <300 IU/day, 0.49; HR per 400 IU/day increase was 0.46). The inverse association was significant and appeared more evident for dietary sources of vitamin D than supplemental vitamin D (HR per 400 IU/day increase 0.77). For CRC precursors, ORs per 400 IU/day increase were 0.76 for conventional adenoma and 0.85 for serrated polyp.

It was concluded that in a cohort of younger women, higher total vitamin D intake was associated with decreased risks of early-onset CRC and precursors.

Kim, H., Lipsyc-Sharf, M., Zong, X., et al. “Total Vitamin D Intake and Risks of Early-Onset Colorectal Cancer and Precursors.”  Gastroenterology 2021; Vol. 161, pp. 1208-1217, October 2021.

Download Tables, Images & References

Pancreatic Cyst Fluid Glucose in Diagnosis of Mucinous Pancreatic Cysts

Read Article

A study was carried out to perform a systematic review and meta-analysis to evaluate the diagnostic characteristics of pancreatic cyst fluid glucose, compared with CEA for pancreatic cystic lesions. Individualized searches were developed in accordance with preferred reporting items for systematic reviews and meta-analyses and meta-analysis of observational studies and epidemiologic guidelines and meta-analysis analyzed according to Cochrane diagnostic test accuracy working group methodology. A bivariate model was used to compute pooled sensitivity and specificity, likelihood ratio, diagnostic odds ratio and summary, receiving operating characteristics curve for intracystic glucose or CEA alone or in combination testing.

Eight studies (609 lesions), mean patient age 63.56 years; 60.36% women were included. The pooled sensitivity for pancreatic cyst fluid glucose was significantly higher compared with CEA alone (91%), with no difference in specificity (86%).  Diagnostic accuracy was significantly higher for pancreatic cyst fluid glucose vs CEA alone (94% vs 85%). Combination testing with pancreatic cyst fluid glucose and CEA did not improve the diagnostic accuracy, compared with glucose alone (97% vs 94%).  It was concluded that low pancreatic cyst fluid glucose was associated with high sensitivity and specificity with significantly improved diagnostic accuracy, compared with CEA alone, with a diagnosis of mucinous vs nonmucinous pancreatic cyst lesion.

McCarty, C., Garg, R., Rustagi, T. “Pancreatic Cyst Fluid Glucose in Differentiating Mucinous From Nonmucinous Pancreatic Cysts: A Systematic Review and Meta-Analysis.”  Gastrointestinal Endoscopy 2021; Vol. 94, pp. 698-712.

Download Tables, Images & References

FROM THE LITERATURE

Common Bile Duct Dilation

Read Article

To determine the role of EUS in the exclusion of benign and malignant pathology that might require further intervention in the presence of asymptomatic common bile duct dilation (CBD), the yield of EUS evaluation for this indication was evaluated through systematic review, attempting to appraise the yield of EUS interpretation in asymptomatic patients with radiologic evidence of that dilation.

A protocolled search (PROSPERO: CRD42020193428) extracted original studies from the Cochrane Library, Ovid Embase, Google Scholar, Ovid Medline, PubMed, Scopus, and Web of Science Core Collection, that described diagnostic yield of EUS among asymptomatic patients with biliary dilation. Cumulative EUS diagnostic yield was calculated through meta-analysis of proportions, using inverse variance methods and a random-effects model. 

Of 2,616 studies, 8 delineated the EUS yield among 224 asymptomatic patients. The cumulative yield of EUS for any pathology was

11.2%. The EUS yield for benign etiologies was 9.2%, of which choledocholithiasis comprised 3.4% and malignant etiologies 0.5% of cases. It was concluded that EUS in patients with asymptomatic CBD dilation does yield findings of choledocholithiasis and malignancy, albeit at low rates. Clinical decision-making plays a role in its application.

Choda, A., Dawod, S., Grimshaw, A., et al.  “Evaluation of Diagnostic Yield of EUS Among Patients with Asymptomatic Common Bile Duct Dilation:  Systematic Review and Meta-Analysis.”  Gastrointestinal Endoscopy, Vol. 94, No. 5:  2021, pp. 890-901.

Download Tables, Images & References

FROM THE LITERATURE

Effectiveness of Vaccination in COVID-19

Read Article

To explore real-world effectiveness of coronavirus disease 2019 (COVID-19) vaccination on subsequent infection in patients with IBD with diverse exposure to immunosuppressive medications, a retrospective cohort study of patients in the VA with IBD diagnosed before December 18, 2020, the start date of the VHA patient vaccination program was carried out. 

IBD medication exposures included mesalamine, thiopurine, anti-tumor necrosis factor virologic agents, vedolizumab, ustekinumab, tofacitinib, methotrexate, and corticosteroid use. Inverse probability weighting and Cox’s regression were utilized with vaccination status as a time-updating exposure and computed vaccine effectiveness from incidence rates. 

A total of 14,697 patients, 7,321 of whom received at least 1 vaccine dose (45.2% Pfizer, 54.8% Moderna) were included. The cohort had median age 68 years, 92.2% were men, 80.4% were white and 61.8% had ulcerative colitis. In follow-up data through April 20, 2021, unvaccinated individuals had the highest raw proportion of SARS-CoV-2 infection (197 {1.34%} vs. 7 {0.11%}) fully vaccinated). Full vaccination status, but not partial vaccination status was associated with a 69% reduced hazard of infection relative to an unvaccinated status (HR 0.31), corresponding to an 80.4% effectiveness.

It was concluded that full vaccination (>7 days after the second dose), against SARSCoV-2 infection has an 80.4% effectiveness in a broad IBD cohort with diverse exposure to immunosuppressive medications. These results may increase patient and provider willingness to pursue vaccination in these settings. 

Khan, N., Mahmud, N. “Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients with Inflammatory Bowel Disease with Diverse Exposure to Immunosuppressive Medications.” Gastroenterology 2021; Vol. 161, pp. 827-836.

Download Tables, Images & References

FROM THE LITERATURE

Transpapillary Gallbladder Stent Placement for Long-Term Therapy of Acute Cholecystitis

Read Article

Select patients with acute cholecystitis (AC) may be poor candidates for cholecystectomy. ERCP-guided transpapillary gallbladder (GB) drainage (ERGD), gives one modality for nonoperative management of AC in these patients to evaluate the long-term success of destination ERGD and determine the rate of technical and clinical success, number of repeat procedures, rate of adverse events, and risk factors for recurrent AC were evaluated.

Consecutive patients with AC, who were not candidates for cholecystectomy underwent ERGD with attempted transpapillary GB plastic, double-pigtail stent placement in a tertiary hospital from January 2008 to December 2019. Long term success was defined as no AC after ERGD until 6 months, death, or reintervention. Technical success was defined as placement of at least 1 transpapillary stent into the GB and clinical success as resolution of AC symptoms with discharge from the hospital.  

Long-term success was achieved in 95.9% of patients (47/49), technical success in 96% (49/51), and clinical success 100% in those with technical success. Mild adverse events occurred in 5.9% (N=3).  Mean follow-up was 453 days after ERGD (range, 18-1879). A trend toward longer time for recurrence of AC was seen in patients with 2, rather than 1 GB stent placed and more repeat procedures were performed when a single stent was placed. It was concluded that ERGD with transpapillary GB double-pigtail stent placement was a safe and effective long-term therapy for a poor surgical candidate with AC. Risk factors for recurrence include stent removal and single-stent therapy. Double-stent therapy is not always technically feasible, but may salvage failed single-stent therapy or recurrence after elective stent removal and may therefore be the preferred treatment modality.

Storm, A., Vargas, E., Chin, J., et al.  “Transpapillary Gallbladder Stent Placement for Long-Term Therapy of Acute Cholecystitis.”  Gastrointestinal Endoscopy, 2021; Vol. 94, pp. 742-748.

Download Tables, Images & References

MEDICAL BULLETIN BOARD

Cardinal Health and Gastrologix Announce Agreement to Provide Access to Specialty Medicines for Gpo Members

Read Article

DUBLIN, OHIO – Cardinal Health Specialty

Solutions and Gastrologix, the only gastroenterologyspecific group purchasing organization (GPO) in the United States, working in conjunction with the Digestive Health Network (DHN), have announced an agreement which designates Cardinal Health’s Metro Medical business as the primary supplier of pharmaceutical products for Gastrologix GPO and DHN members, providing expanded access to critical medicines for GI patients nationwide.

“Gastrologix is a leader in providing technology and practice management solutions to the GI market. We are excited to marry their solutions with our best-in-class distribution capabilities to support the unique needs of independent gastroenterology practices, enabling providers to focus their time on positively impacting patient care,” said Dan Duran, Senior Vice President and General Manager, Provider Solutions, Cardinal Health Specialty Solutions.

“Independent GI practices face many challenges in working to provide high quality care at lower costs. The members of our GPO deal daily with healthcare consolidation, rising costs and declining reimbursements,” said Stephen Somers, Principal at Gastrologix. “Cardinal Health Specialty Solutions is the perfect partner because they believe in tailoring programs to the individual needs of a practice and its patients. We look forward to working with them to provide our members with optimal contract pricing on specialty medications, as well as data analytics and specialized expertise. Our partnership with Cardinal Health will help our member practices thrive.”

Cardinal Health has one of the largest healthcare supply chains in the U.S. with strategically located distribution centers that enable fast and efficient delivery anywhere in the U.S. Through Specialty Solutions, Cardinal Health supports communitybased practices across the nation with specialties in oncology, urology, nephrology, rheumatology, gastroenterology, ophthalmology, neurology, and immunology.

About Gastrologix

Gastrologix is the only Group Purchasing Organization (GPO) in the U.S. working strictly on behalf of independent gastroenterologists. Gastrologix helps practices lower costs, operate more efficiently and expand services, so that GI physicians can remain independent to provide a valuable healthcare alternative.

Information about Gastrologix is available at: gastrologix.net

About Cardinal Health

Cardinal Health (NYSE: CAH) is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in business, operations in more than 35 countries and approximately 44,000 employees globally, Cardinal Health is essential to care.

In working on behalf of our independent GI practice members, Gastrologix has developed the largest purchasing channel for infusion therapies in the Gastroenterology market. Contact us to find out how your practice can benefit from our collective efforts.

Download Tables, Images & References

MEDICAL BULLETIN BOARD

Health Equity Requires Understanding Diversity of Patient plus Coordinated Inclusion Strategy

Read Article

Major health systems are recognizing that health equity is only feasible when comprehensive, coordinated initiatives link quality of care to a culture of inclusion. Dr. Maria Hernandez, founder of Impact4Health, has seen increasing concerns and demands for more engagement among clinicians and administrators to address unconscious bias, culturally effective care and involving community partners in healthcare.

Oakland, CA —The pandemic has brought to light inequities in our health care system that are undeniable, but it’s a problem that has languished long before disaster struck.1 Dr. Maria Hernandez, founder of Impact4Health, says healthcare organizations have a clear and present responsibility to improve, equity and inclusion efforts in order to better service patients and their families.

The Association of American Medical Colleges wrote as recently as 2019, “To effectively enact institutional change at academic medical centers and leverage the promise of diversity, leaders must focus their efforts on developing inclusive, equity-minded environments. A shared desire for change, aided by a growing number of resources, will enable medical schools and academic health centers to assess their institutional culture and climate and improve their capacity for diversity and inclusion”.2

However, each issue can cause different challenges, and measuring those differences presents a broad range of challenges, not only in collecting data but in taking action on that information.

“In training physicians about unconscious bias, most will quickly say that they treat every patient the same, but that’s a problem” explains Dr. Hernandez. “Treating everyone the same assumes all patients have the same resources or live in the same conditions and that’s painfully not the case. Hospital services need to take into account different backgrounds, history, and issues related to our multicultural society. Inclusion is what you do about that diversity to ensure that this diverse population not only feels that they are welcomed and belong, but truly get the right care that meets their needs.”

A culture of inclusion is also of value to diverse staff. Physicians of color have increasingly voiced concerns about how they experience the work environment.  “In every training session, we are hearing how often they are subjected to bias by patients or other staff. Left unaddressed, these experiences take their toll on professionals”, say Hernandez.

The growing diversity of patients and staff is no longer a question. But creating a culture of inclusion is a strategic choice when it comes to recruitment, training and designing patient services in healthcare systems.

“Diversity is being asked to the party,” explains Dr. Hernandez. “Inclusion is being asked to dance.” The real-world examples of the benefits of inclusion are manifold, but to name just a few:

  • Higher levels of morale, largely due to a sense of being part of a larger community
  • Better care for diverse populations from an inclusive staff that includes team members who can identify patients, communicate with them, and better serve their unique needs
  • Better problem solving because staff have a better understanding where their patients are coming from, both physically and culturally

Dr. Denis Nash, an epidemiologist and executive director of the City University of New York Institute for Implementation Science in Population Health (ISPH) says, “We live in a

country where your wealth and your socioeconomic status is a big determinant for how healthy you are, how long you will live, and whether you live with a higher burden of disease while you’re alive”.3 This growing knowledge that diverse patients bring different health needs is at the heart of new initiatives to improve healthcare now.

Naturally, training and education are key to expanding the values of inclusion. Diversity in hiring practices goes a long way but nurturing inclusivity among all staff improves not only better health results, but better patient interaction and cooperation. Diversity training helps increase culturally effective care by teaching staff how to respond to cultural differences; identifying

and mitigating personal, subconscious and unconscious bias, and acknowledging potential barriers to care based on cultural differences or access to key resources.

The goal, obviously, is better health outcomes and training and acknowledgement of the issues involved is a good place to start. Impact4Health’s free Inclusion Scorecard for Population Health is a valuable tool that can serve as a powerful catalyst for a shift in a facility’s culture. “The Scorecard is a key tool for health systems to assess where they are in this journey and target key activities for their health equity strategy,” explains Dr. Hernandez. It’s what we do about that diversity that matters, especially when it comes to inclusion and how we treat people, and really, just putting people at ease. If someone is your advocate—whether it’s a friend, family member, or a hospital employee— when we put people at ease because they’re around people who either look like them, or understand their unique needs , healthcare outcomes improve.

“This is important. If you talk about health equity, then you need to walk the talk,” says Hernandez. “This is a radical change in how healthcare actually works, so naturally it’s not going to be easy. This issue isn’t solved behind a desk—it’s in our waiting rooms, our exam spaces, and in every interaction that we have with patients, regardless of their cultural or racial background. The better we understand each other, the closer we are to real healthcare equity.”

AboutImpact4Health

Impact4Health is a multidisciplinary team of community psychologists, public health researchers, physicians and health educators who promote health equity, working in partnership with hospitals, public health departments, and healthcare insurance providers. Strategies employed include training in cross-cultural health, inclusive leadership, and implementing the Inclusion Scorecard for Population Health. Impact4Health is also a leader in the development of health-related Pay For Success initiatives to address asthma-related emergencies for children living in vulnerable communities.

For more information, please visit us at:

Impact4Health.com

  1. McKinskey & Company  “Diversity Wins: How Inclusion Matters” mckinsey.com/featured-insights/ diversity-and-inclusion/diversity-wins-how-inclusionmatters Accessed May 2021
  2. Association of American Medical Colleges “Diversity in Medicine: Facts and Figures 2019” aamc.org/datareports/workforce/interactive-data/fostering-diversityand-inclusion Accessed May 2021
  3. Diverse Issues in Higher Education “COVID-19 Pandemic Highlights Need to Diversify Healthcare Workforce” diverseeducation.com/article/183296/

Accessed May 2021

Download Tables, Images & References

NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #217

Pathophysiology-Guided Nutrition Support in Critical Illness

Read Article

Nutrition care guidelines offer differing recommendations about protein and energy provision in critical illness. The lack of agreement is not surprising, when one considers the heterogeneity of critical illness, the complexity and imperfect delivery of nutritional prescriptions, and the inconclusive results of randomized clinical trials of nutrition support in critical illness. The recommendations in the guidelines are meticulous and important, but they do not provide physiologically informed advice about the selection of nutritional regimens for individual patients. This review explains a practical strategy of bedside nutritional-metabolic evaluation that clinicians may use to formulate nutritional regimens appropriate to the situation of individual critically ill patients.

INTRODUCTION

Evidence based medicine (EBM) operates on the principle that high-quality randomized clinical trials (RCTs) yield the most reliable evidence on which to base clinical decisions.  As corollaries of this principle, EBM discounts expert judgment (it is unreliable and prone to bias) and physiological evidence (it is irrelevant as to whether a therapy is, in fact, effective). Yet clinical judgment and physiological reasoning remain crucial elements of sound clinical practice.

Physiological reasoning is necessary to design RCTs intelligently and interpret their results properly. For example, a clinical trial of iron therapy that enrolls patients with any kind of anemia will be useless or worse, no matter how excellent its technical quality. Individualized patient care requires both clinical judgment and physiological reasoning to evaluate the relevance of patient-specific factors to specific situations, and deal with the uncertainties and gaps that exist in EBM-based guidelines.1,2 Clinicians ought to be able to understand and explain why they choose to follow a particular guideline recommendation when caring for a specific patient, a process that requires clinical judgment and physiological reasoning.1

Physiological reasoning is especially important in critical illness, which creates hindrances to the design, execution and interpretation of RCTs. These hindrances include the many syndromic and sometimes vague definitions of critical illness, enormous heterogeneity within these syndromes, the confounding effects of co-morbidities, practical difficulties executing small-enrollment clinical trials, and the absence of sex-disaggregated data.1 Clinical trials of nutritional therapies face yet greater challenges, for they involve varying combinations of nutrients, are difficult to implement, and relatively infrequently carried out. A problem unique to nutritional therapies is the large discrepancy between targeted and delivered nutrient doses in published clinical trials.3-5

The physiological heterogeneity of critical illness has important nutritional implications. For example, the advantages and disadvantages of two frequently studied critical-illness nutrition interventions – low-energy, protein-deficient nutrition (known as “permissive underfeeding”6) on the one hand, versus high-energy and potentially energy-toxic, but higher-protein nutrition on the other – would be expected to accrue differently to patients with different critical-illness metabolic phenotypes. Considerations like this seriously challenge the value of blanket conclusions about any one-size-fits-all nutritional regimen in critical illness.7 It is not surprising that, as with critical illness in general,8 no critical-illness nutrition regimen has been shown to be superior to another one.3,9-13

This is where physiological reasoning comes in. This article provides a practical strategy of physiologically-guided bedside nutritional evaluation that clinicians may use to formulate macronutrient (protein and energy) prescriptions relevant to the situation of individual critically ill patients.

Pathophysiology-Guided Nutritional Evaluation

Examine the patient’s muscles. Muscles account for most of the body’s lean tissue mass, which is the main determinant of a person’s resting energy expenditure and minimum protein requirement. Protein requirements are conventionally indicated in relation to body weight (BW) because normal BW is a useful surrogate for lean tissue mass.14 But BW can be difficult to measure in the intensive care unit, and even when accurately measured it is frequently unreliable, for it overestimates the lean tissue mass of volume-expanded and obese patients.15 How, then, should one determine a critically ill patient’s “metabolically effective” BW – the BW that reflects their existing lean tissue mass

undistorted by excess adipose tissue or extracellular fluid (ECF)? Various empirical methods have been suggested.16 I suggest the physiologically logical approach of evaluating the patient’s muscles, subcutaneous adipose tissue and ECF volume. After integrating the physical findings, settle on a numeric value for the patient’s adipose tissuenormalized, dry (i.e., ECF-normalized) body mass index (BMI; kg/m2). Then measure or estimate the patient’s height (small errors only trivially affect the result) and calculate their “normalized (obesitycorrected) dry (ECF-corrected) BW” (NDBW). For example, after consciously discounting any excessive adipose tissue and edema, one might judge the overall muscular profile of a ~ 1.75m (175cm) adult to be consistent with a BMI of ~23 kg/m.2 This patient’s NDBW is (1.75)2 X 23 = ~ 70 kg. Visual BMI is easy to learn, first by practicing and verifying it on non-obese, non-edematous patients, then extrapolating the skill to patients whose body composition is modified by obesity, edema and even ascites.

Muscle atrophy has many, usually combined, causes. They include the muscle atrophy that occurs in simple starvation disease, chronic systemic inflammation, old age (sarcopenia), disuse muscle atrophy from prolonged inactivity, and as a consequence of glucocorticoid therapy, endocrine pathology (adrenal insufficiency, cortisol excess, pituitary deficiency, testosterone deficiency), and primary neurological or muscle disease.17 It is important to identify the reasons why a patient has developed muscle atrophy, but the protein dose in their nutritional prescription is determined by severity, not etiology.

Point of care devices capable of indicating the mass of selected muscle groups are rapidly being perfected.18,19 The sarcopenia index, which relates the renal clearance-adjusted serum creatinine concentration to muscle mass, is a potentially useful addition.20 As such techniques become validated and incorporated into routine clinical use they may complement, but should not replace, conscientious, bedside physical examination of the patient to immediately identify absent, mild, or severe generalized muscle atrophy.21-23 Evaluate the severity of the patient’s proteincatabolic state and associated rate of muscle atrophy to determine the appropriate amount of protein to provide them.24 The rate of body protein loss is determined by measuring nitrogen (N) excretion (or N balance in the fed state).25 In hospital settings, N balance measurements are accurate and precise enough to determine whether protein catabolism is mild, moderate, or severe, and they are especially practical in intensive care units, where protein or amino acid intake is easily quantified and oneon-one nursing makes accurately timed urine collections feasible. Direct analysis of urinary total N is not possible in most intensive care units, but it may be calculated as the sum of the N in urea, ammonium, and creatinine; formulas are available that extrapolate it from urinary urea N alone. The best-known formula estimates total N loss (g/day) as urinary urea N + 4.  A more recent one estimates it as urinary urea N/0.85 + 2.25

As a rule of thumb, urinary N excretion (or negative N balance in the fed state) > 10 g/day in a 70 kg adult may be regarded as severe protein catabolism.26-31 This rate of N loss corresponds to the loss of 62 g protein and 300 g lean tissue/day;25 few knowledgeable clinicians would dispute the assertion that someone losing > 2 kg muscle mass/ week is experiencing severe protein catabolism.

Despite its face validity, technical ease and acceptable precision,25,32-35 N balance is too often ignored in modern intensive care practice,5 with preference given to a variety of critical illness severity scores. These scores were developed and validated to predict the risk of death, not the rate of body protein loss.9,36 They have never been shown to predict severity of protein catabolism. Their use for this purpose is neither validated nor physiologically rational.

In principle, a protein-catabolic severity score could be developed by measuring N excretion (N balance in the fed state) and relating it to predictive factors such as NDBW, age, sex, disease category, and pertinent biomarkers. Once validated, such a score could predict a patient’s rate of body protein loss in the same way the Harris-Benedict equations predict resting energy expenditure.37 Unfortunately, no predictive equation of this kind currently exists. The current state of affairs leaves no rational alternative to measuring N excretion (N balance in the fed state) to determine protein catabolic severity.

Some patients have normal muscle mass when their critical illness develops, but many others suffer from pre-existing muscle atrophy.38 Protein-catabolic patients with pre-existing muscle atrophy will lose less muscle protein per day in absolute terms than equivalently protein-catabolic patients with normal muscle mass, but they are in greater danger. They are close to the cliffedge of lethal muscle atrophy, and their atrophic muscles cannot sustain normal respiratory function or release enough amino acids into the central amino acid pool for acute-phase protein synthesis, immunoregulation and wound healing.9,24 For these reasons, and because muscle atrophy is so common in modern intensive care units, it is appropriate to define severe catabolic N loss as > 150 mg/kg NDBW/day.

In conclusion, when a critically ill patient is experiencing rapid muscle atrophy, it is physiologically rational to provide protein or amino acids promptly (in a handful of hours or days) in a dose suggested by the severity of their rate of body protein loss; this decision is independent of the patient’s syndromic critical illness category. Conversely, when a patient has normal muscle mass and their rate of muscle loss is moderate, the protein dose and urgency of providing it are less.

Estimate the patient’s fuel reserve by examining their subcutaneous adipose tissue. An edemadiscounted BMI > 18 kg/m2 indicates that the patient has enough fat to sustain normal bioenergetics for at least a few weeks of hypoenergetic nutrition support.

Examine for risk factors and indications of exogenous energy substrate resistance3 – more generally called anabolic resistance39 – which exposes patients to the toxic effects of energy overfeeding. Energy substrate resistance commonly manifests as hyperinsulinemia, hyperglycemia, and hypertriglyceridemia.40 Critical illness both creates energy resistance and amplifies preexisting anabolic resistance due to non-insulin dependent diabetes mellitus, obesity, old age, renal dysfunction, or glucocorticoid therapy.

Since all methods for estimating energy

expenditure are imprecise,41,42 successful provision of what is intended to be isoenergetic nutrition unavoidably overfeeds some patients. Except in cases of severe fat depletion, the energy dose for a critically ill patient should not routinely be set equal to energy expenditure, but reduced below it: the more severe the energy resistance, the greater the toxicity of exogenous energy provision.3,43 This suggestion is supported by the repeated failure of RCTs of high-energy, high fluid-volume nutrition support to improve the clinical outcomes of critically ill patients, with suggestions of harm to some of them.3,5,13,16,44,45

Evaluate for coexisting micronutrient deficiencies.46 Intracellular deficiencies of potassium, zinc, magnesium, and possibly other micronutrients likely prevent the efficient utilization of amino acids for protein synthesis.

Selection of Protein and Energy Targets

The preceding discussion makes it clear that appropriate doses of protein and energy, and the urgency of successfully delivering them, are independent of one another.

 Protein. The doses of protein recommended in current guidelines range from 1.3 to 2.5 g/kg/day.6,16 When deciding which dose to provide a specific patient, consider two factors that are known to increase the minimum protein requirement:

  1. hypoenergetic nutrition, which increases the protein requirement of non-critically ill patients and likely does the same in critical illness;47
  2. severe systemic inflammation, which increases net muscle proteolysis under conditions in which the amino acids released from muscle (as well as dietary amino acids) are inefficiently reincorporated into proteins elsewhere in the body and hence are oxidized and lost.48

For these reasons, provide 1.3 to 1.5 g protein/ kg NDBW/day (approximately twice the normal adult minimum protein requirement of 0.8 g/kg/ day) during hypoenergetic nutrition of any patient – a nutritional regimen known as hypocaloric highprotein nutrition.3,35,43 Provide higher doses, up to 2.5 g/kg NDBW/day, to patients with increasingly severe protein catabolism.35 When prescribing parenteral nutrition bear in mind that, unlike with intact protein, free amino acids are hydrated; the additional molecule of water attached to each amino acid reduces the mass of protein substrate delivered to the patient. Thus, 100 g of a mixture of free amino acids delivers ~ 83 g protein substrate.25 Energy. Critical-care nutrition care guidelines have traditionally recommended isoenergetic nutrition, but this view is changing. Physiological reasoning and the current RCT evidence do not justify the routine provision of isoenergetic nutrition to patients with an adequate store of body fat. The European Society for Clinical Nutrition16 now defines energy provision as low as 70% of estimated energy expenditure as “normocaloric.” The American Society for Parenteral and Enteral Nutrition and Society of Critical Care Medicine6 recommend hypocaloric high-protein nutrition for morbidly obese patients, although they do so without explaining why this recommendation should not extend to all patients who have ample or adequate body fat.3

Table 1 summarizes the physiological factors that should be evaluated when formulating a critically ill patient’s protein and energy prescription: they are muscle mass, proteincatabolic severity, adipose tissue reserve, and energy resistance. For simplicity, protein-catabolic severity and energy resistance are included under one heading, because both conditions increase the dietary protein requirement.

Convergence of EBM and Physiological Reasoning in Individualized Patient Care

Physiological reasoning enriches and complements EBM by providing clinicians with principles and conceptual tools they can use to reason for themselves about individual patients, and when confronted by gaps and disagreements within and between different clinical care guidelines. The principles summarized in this article are well known and uncontroversial.26,42,49 It would be a straightforward and desirable exercise to include them in the design of large RCTs. Unfortunately,

this has not yet happened. The reasons why physiological reasoning has been neglected in RCT design may be rooted in the history and evolution of critical-care nutrition research.3,9 For many years, clinical trial experts shone their investigative searchlight narrowly on energy provision, to the near-exclusion of protein. This “streetlight effect”50 can, to a large extent, be attributed to the ready availability and convenience of using premanufactured nutrition products with a fixed, low protein-to-energy ratio that is appropriate in normal nutrition, but unsuited to the pathophysiology of protein-catabolic illness.3,9,51-53 Even today, proteindeficient permissive underfeeding and hypocaloric high-protein nutrition continue to be confused or conflated in some of the critical care literature.    

Indeed, until recently it was not feasible – and it still may not be in some intensive care units – to deliver either adequate amounts of protein, or appropriately generous amounts of it without energy-overfeeding some patients. This no longer has to be the case. High amino-acid parenteral nutrition products and devices are now available that allow independent selection of amino acid and dextrose doses.54 Similarly, enteral nutrition products and techniques are now available that allow independent selection of protein and energy doses and hence the provision of appropriately generous amounts of protein without energy overfeeding.5,54-56

The defining feature of individualized patient care is its focus on the individual. Many of the procedures explained in this article depend on information and insight obtained by astute physical examination of the patient. An added benefit of this process is that in carrying it out, clinicians are reminded that their patients are neither algorithms nor scores, but specific, unique individuals.

CONCLUSION

Critical-care nutrition guidelines are important. Their chief responsibility is to assess, compile and evaluate high-quality clinical evidence, especially the evidence derived from RCTs; but RCTs alone do not tell the whole story. Physiological reasoning, by itself, is an unreliable guide to clinical decisions, but this fact does not justify the absurd bias that physiological reasoning can be ignored when designing RCTs and interpreting their results. Many critical-care nutrition RCTs have been poorly informed by physiological insight, and they have relied on nutrition products ill-suited to the pathophysiology of critical illness. The metabolic heterogeneity of critical illness mitigates against any one-size-fits-all approach to nutritional recommendations. The principles explained in this article fit within the envelope of existing guidelines, while providing a conceptual framework that clinicians can use to make personal, physiologically rational decisions about the nutritional support of individual patients.

References

  1. Tonelli MR, Curtis JR, Guntupalli KK, et al. An official multi-society statement: the role of clinical research results in the practice of critical care medicine. Am J Respir Crit Care Med. 2012;185:1117-24.
  2. Cortes-Puch I, Applefeld WN, Wang J, et al.
    Individualized care is superior to standardized care for the majority of critically ill patients. Crit Care Med. 2020;48:1845-7.
  3. Hoffer LJ. High-protein hypocaloric nutrition for non-obese critically ill patients. Nutr Clin Pract. 2018;33:325-32.
  4. Wischmeyer PE. Overcoming challenges to enteral nutrition delivery in critical care. Curr Opin Crit Care. 2021;27:169-76.
  5. De Waele E, Jakubowski JR, Stocker R, et al. Review of evolution and current status of protein requirements and provision in acute illness and critical care. Clin Nutr. 2021;40:2958-73.
  6. McClave SA, Taylor BE, Martindale RG, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (ASPEN). JPEN J Parenter Enteral Nutr. 2016;40:159-211.
  7. Schuetz P. Food for thought: why does the medical community struggle with research about nutritional therapy in the acute care setting? BMC Med. 2017;15:38.
  8. Vincent JL. We should abandon randomized controlled trials in the intensive care unit. Crit Care Med. 2010;38:S534-8.
  9. Hoffer LJ, Bistrian BR. Nutrition in critical illness:
    a current conundrum. F1000Res. 2016;5 (F1000 Faculty Rev):2531.
  10. Stoppe C, Wendt S, Mehta NM, et al. Biomarkers in critical care nutrition. Crit Care. 2020;24:499.
  11. Sharma K, Mogensen KM, Robinson MK. Pathophysiology of critical illness and role of nutrition. Nutr Clin Pract. 2019;34:12-22.
  12. Fuentes Padilla P, Martinez G, Vernooij RW, et al. Early enteral nutrition (within 48 hours) versus delayed enteral nutrition (after 48 hours) with or without supplemental parenteral nutrition in critically ill adults. Cochrane Database Syst Rev. 2019;10:31.
  13. van Niekerk G, Meaker C, Engelbrecht AM. Nutritional support in sepsis: when less may be more. Crit Care. 2020;24:53.
  14. Earthman CP, Wolfe RR, Heymsfield SB. Dudrick Research Symposium 2015-Lean Tissue and Protein in Health and Disease. JPEN J Parenter Enteral Nutr. 2017;41:226-37.
  15. Gonzalez MC, Correia M, Heymsfield SB. A requiem for BMI in the clinical setting. Curr Opin Clin Nutr Metab Care. 2017;20:314-21.
  16. Singer P, Blaser AR, Berger MM, et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr. 2019;38:48-79.
  17. Prado CM, Purcell SA, Alish C, et al. Implications of low muscle mass across the continuum of care: a narrative review. Ann Med. 2018;50:675-93.
  18. Looijaard W, Molinger J, Weijs PJM. Measuring and monitoring lean body mass in critical illness. Curr Opin Crit Care. 2018;24:241-7.
  19. Lambell KJ, Earthman CP, Tierney AC, et al. How does muscularity assessed by bedside methods compare to computed tomography muscle area at intensive care unit admission? A pilot prospective cross-sectional study. J Hum Nutr Diet. 2020;31:31.
  20. Lopez-Ruiz A, Kashani K. Assessment of muscle mass in critically ill patients: role of the sarcopenia index and images studies. Curr Opin Clin Nutr Metab Care. 2020;23:302-11.
  21. Esper DH. Utilization of nutrition-focused physical assessment in identifying micronutrient deficiencies. Nutr Clin Pract. 2015;30:194-202.
  22. Fischer M, JeVenn A, Hipskind P. Evaluation of muscle and fat loss as diagnostic criteria for malnutrition. Nutr Clin Pract. 2015;30:239-48.
  23. Bistrian BR, Mogensen KM, Christopher KB. Plea for reapplication of some of the older nutrition assessment techniques. JPEN J Parenter Enteral Nutr. 2020;44:391-4.
  24. Hoffer LJ, Dickerson RN, Martindale RG, et al. Will we ever agree on protein requirements in the intensive care unit? Nutr Clin Pract. 2017;32:94S-100S.
  25. Hoffer LJ. Human protein and amino acid requirements. JPEN J Parenter Enteral Nutr. 2016;40:460-74.
  26. Blackburn GL, Bistrian BR, Maini BS, et al. JPEN J Parenter Enteral Nutr 1977;1:11-22.
  27. Shenkin A, Neuhauser M, Bergstrom J, et al. Biochemical changes associated with severe trauma. Am J Clin Nutr. 1980;33:2119-27.
  28. Greig PD, Elwyn DH, Askanazi J, et al. Parenteral nutrition in septic patients: effect of increasing nitrogen intake. Am J Clin Nutr. 1987;46:1040-7.
  29. Pitkanen O, Takala J, Poyhonen M, et al. Nitrogen and energy balance in septic and injured intensive care patients: response to parenteral nutrition. Clin Nutr. 1991;10:258-65.
  30. Frankenfield DC, Smith JS, Cooney RN. Accelerated nitrogen loss after traumatic injury is not attenuated by achievement of energy balance. JPEN J Parenter Enteral Nutr. 1997;21:324-9.
  31. Dickerson RN, Pitts SL, Maish GO, III, et al. A reappraisal of nitrogen requirements for patients with critical illness and trauma. J Trauma Acute Care Surg. 2012;73:549-57.
  32. Dickerson RN. Using nitrogen balance in clinical practice. Hosp Pharm. 2005;40:1081-5.
  33. Graves C, Saffle J, Morris S. Comparison of urine urea nitrogen collection times in critically ill patients. Nutr Clin Pract. 2005;20:271-5.
  34. Dickerson RN, Maish GO, III, Croce MA, et al.
    Influence of aging on nitrogen accretion during critical illness. JPEN J Parenter Enteral Nutr. 2015;39:28290.
  35. Dickerson RN. Protein requirements during hypoca-
    loric nutrition for the older patient with critical illness and obesity: an approach to clinical practice. Nutr Clin Pract. 2020;35:617-26.
  36. Vincent JL, Opal SM, Marshall JC. Ten reasons why we should NOT use severity scores as entry criteria for clinical trials or in our treatment decisions. Crit Care Med. 2010;38:283-7.
  37. Dickerson RN, Mason DL, Croce MA, et al. Evaluation of an artificial neural network to predict urea nitrogen appearance for critically ill multiple-trauma patients. JPEN J Parenter Enteral Nutr. 2005;29:429-35.
  38. Deutz NEP, Ashurst I, Ballesteros MD, et al. The underappreciated role of low muscle mass in the management of malnutrition. J Am Med Dir Assoc. 2019;20:22-7.
  39. Morton RW, Traylor DA, Weijs PJM, et al. Defining anabolic resistance: implications for delivery of clinical care nutrition. Curr Opin Crit. Care 2018;24:12430.
  40. Green P, Theilla M, Singer P. Lipid metabolism in critical illness. Curr Opin Clin Nutr Metab Care. 2016;19:111-5.
  41. Tatucu-Babet OA, Ridley EJ, Tierney AC. Prevalence of underprescription or overprescription of energy needs in critically ill mechanically ventilated adults as determined by indirect calorimetry: a systematic literature review. JPEN J Parenter Enteral Nutr. 2016;40:212-25.
  42. Berger MM. Nutrition and micronutrient therapy in critical illness should be individualized. JPEN J Parenter Enteral Nutr. 2020;44:1380-7.
  43. Rugeles SJ, Ochoa Gautier JB, Dickerson RN, et al. How many nonprotein calories does a critically ill patient require? A case for hypocaloric nutrition in the critically ill patient. Nutr Clin Pract. 2017;32:72S-6S.
  44. Asrani VM, Brown A, Bissett I, et al. Impact of intravenous fluids and enteral nutrition on the severity of gastrointestinal dysfunction: a systematic review and meta-analysis. J Crit Care Med. 2020;6:5-24.
  45. Messmer AS, Zingg C, Muller M, et al. Fluid overload and mortality in adult critical care patients-a systematic review and meta-analysis of observational studies. Crit Care Med. 2020;48:1862-70.
  46. Blaauw R, Osland E, Sriram K, et al. Parenteral provision of micronutrients to adult patients: an expert consensus paper. JPEN J Parenter Enteral Nutr. 2019;43 Suppl 1:S5-S23.
  47. Dickerson RN, Patel JJ, McClain CJ. Protein and calorie requirements associated with the presence of obesity. Nutr Clin Pract. 2017;32:86S-93S.
  48. Batt J, Herridge M, Dos Santos C. Mechanism of ICU-acquired weakness: skeletal muscle loss in critical illness. Intensive Care Med. 2017;10:10.
  49. Wolfe RR. The 2017 Sir David P Cuthbertson lecture. Amino acids and muscle protein metabolism in critical care. Clin Nutr. 2017;21:21.
  50. Lernmark A. The streetlight effect–is there light at the end of the tunnel? Diabetes. 2015;64:1105-7.
  51. Hoffer LJ, Bistrian BR. Why critically ill patients are protein deprived. JPEN J Parenter Enteral Nutr. 2013;37:300-9.
  52. Hoffer LJ, Bistrian BR. Why critically ill patients are protein deprived. JPEN J Parenter Enteral Nutr. 2013;37:441.
  53. Hoffer LJ. Protein requirement in critical illness. Appl Physiol Nutr Metab. 2016;41:573-6.
  54. Hoffer LJ. Parenteral nutrition: amino acids. Nutrients. 2017;9:10.
  55. Hopkins B, Cohen SS, Irvin SR, et al. Achieving protein targets in the ICU using a specialized highprotein enteral formula: a quality improvement project. Nutr Clin Pract. 2020;35:289-298.
  56. ApSimon M, Johnston C, Winder B, et al. Narrowing the protein deficit gap in critically ill patients using a very high-protein enteral formula. Nutr Clin Pract. 2020;35:533-9.

Download Tables, Images & References

Jojobet GirişjojobetmeritbetcasibomCasibom girişcasibomromabetJojobet GirişcasibomcasibomcasibomjojobetMadridbetMadridbetcasibom giriştaraftarium24justin tvbetgaranti girişganobetpokerklasjojobetjojobetromabetMarsbahis GüncelCasibommatbetJojobetGrandPashaBet destekDeneme bonusu veren siteler 2026GrandPashaBet Şikayetjojobet girişholiganbetCasibom GirişJojobet GirişJojobet Giriş